In a significant development for drug policy and mental health treatment, President Trump signed an executive order on Saturday, April 18, 2026, aimed at accelerating the review process for psychedelic drugs, including ibogaine. This directive instructs the Food and Drug Administration (FDA) to expedite its review of these substances, which hold promise for treating conditions such as post-traumatic stress disorder (PTSD) and substance abuse. The initiative, detailed by Reuters and The Guardian, also allocates $50 million towards federal research into ibogaine, a substance derived from a central African shrub root that has shown potential in treating opioid addiction. This move is expected to pave the way for reclassification of these drugs following successful clinical trials. The reforms are particularly seen as a boost to Texas, which has already committed substantial funding to ibogaine research.
This push for psychedelic drug treatments aligns with a growing interest in alternative therapeutic approaches for serious mental illnesses. Officials indicated that these reforms could lead to a reclassification of these compounds, many of which are currently largely illegal. The initiative also involves collaboration between the Department of Health and Human Services (HHS), the FDA, the Drug Enforcement Agency (DEA), the Department of Veterans Affairs, and the private sector to enhance clinical trial participation and evidence generation. The Attorney General will also review relevant products for rescheduling upon FDA approval. This represents a notable shift in how the U.S. government is approaching the research and potential therapeutic use of substances that have historically faced significant regulatory hurdles, with potential implications for millions of Americans seeking effective treatments for mental health and addiction challenges.